Skip to main content

Table 1 Demographic, Clinical, and Pathologic Characteristics of 20 men with biochemical recurrent prostate cancer after previous therapy

From: Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy

Patient No. Age (yr.) Race Serum PSA at Initial Diagnosis (ng/ml) Gleason Score at Initial Diagnosis Clinical Stage at Initial Diagnosis Initial Treatment Length of F/U months
1 62 White UNK 3+4 = 7 T3aNxMx RP 12
2 67 White 4.8 3+3 = 6 T2xNxMx Brachy/EBRT/ADT 12
3 67 White UNK 3+3 = 6 T2xNxMx RP 12
4 78 White 4.7 3+4 = 7 T2aNxMx Brachy/EBRT/ADT 6, started ADT
5 77 African American 14.08 UNK T3aNxMx RP/EBRT 12
6 75 White 8.28 4+5 = 9 T2cNxMx ADT/RP 12
7 69 White 10.36 3+3 = 6 T1cNxMx EBRT 12
8 71 White UNK UNK UNK RP/Salvage EBRT 12
9 75 White UNK 4+4 = 8 T2bNxMx EBRT/ADT 12
10 77 White 8.1 4+5 = 9 T3bNxMx RP 3, started ADT
11* 79 White UNK 2+3 = 5 T1cNxMx EBRT 9, withdrew due to side effects
12 68 White UNK 4+4 = 8 T2aNxMx RP/Adjuvant EBRT 6, started ADT
13 76 African American 11.13 3+3 = 6 T2aNxMx EBRT 12
14 79 White 4.0 3+4 = 7 T1cNxMx RP/Adjuvant EBRT 12
15 73 White 10 3+2 = 5 T1cNxMx EBRT 12
16 60 White 9.2 3+4 = 7 T1cNxMx RP/Adjuvant EBRT 12
17 63 White 17.3 4+3 = 7 T1cNxMx EBRT 12
18 70 White 9.8 3+3 = 6 T2xNxMx RP/salvage EBRT 12
19* 76 African American 4.1 3+4 = 7 T2bNxMx RP 6, lost to F/U
20 77 White 8.7 UNK T2aNxMx EBRT 6, lost to F/U
Median 73 --- 9.2 7 --- --- 12
  1. *, noncompliant
  2. Brachy, brachytherapy
  3. EBRT, external beam radiation therapy
  4. RP, radical prostatectomy
  5. ADT, androgen deprivation therapy
  6. F/U, follow-up
\